Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 1/2020

01-01-2020 | Fatty Liver | Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever, Section Editor)

Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis

Authors: Luan Rodrigues Abdallah, Ricardo Cardoso de Matos, Yves Pacheco Dias March e Souza, Débora Vieira-Soares, Gabriela Muller-Machado, Priscila Pollo-Flores

Published in: Current Atherosclerosis Reports | Issue 1/2020

Login to get access

Abstract

Purpose of Review

We summarize best data of the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD).

Recent Findings

NAFLD has been linked with insulin resistance, obesity, and metabolic syndrome, conditions known to be associated with CVD and subclinical atherosclerosis. The rising evidence of the association between NAFLD and subclinical CVD may suggest that NAFLD is not only a marker but also may be actively involved in pathogenesis of CVD.

Summary

It is an overview of previous studies assessing relationships between NAFLD and markers of cardiovascular disease, as the presence of coronary artery calcification, increased arterial stiffness, and elevated carotid media thickness, in order to better understand the interplay between these conditions.
Literature
1.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–128.CrossRefPubMed
2.
Khot U, Khotm M, Bajzer C, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904.CrossRefPubMed
3.
Lazo M. Clark Jm. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–50.CrossRefPubMed
4.
D’Adamo E. Cali Am, Weiss R, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33(8):1817–22.CrossRefPubMedPubMedCentral
5.
Kotronen A, YkiJarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.CrossRefPubMed
6.
Kotronen A, Velagapudi VR, Yetukuri L, et al. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia. 2009;52(4):684–90.CrossRefPubMed
7.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.CrossRefPubMed
8.
Pacifico L. Nobiliv, Anania C, et al. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011;17(26):3082–91.PubMedPubMedCentral
9.
Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118(3):277–83.CrossRefPubMedPubMedCentral
10.
Sorrentino P, Terracciano L, D’Angelo S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMAIR, and hypertension. Am J Gastroenterol. 2010;105(2):336–44.CrossRefPubMed
11.
Youssoni ZM, Blissett D, Blissett T, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86.CrossRef
12.
Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52.CrossRefPubMed
13.
•• Targher G, Byrne C, Lonardo A, et al. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a metaanalysis. J Hepatol. 2016;65(3):589–600 Excelent metaanalysis that quantify themagnitude of the association between NAFLD (and its severity) and risk of CVD events. CrossRefPubMed
14.
15.
Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: Are they coupled? Heart Fail Clin. 2012;8(4):663–70.CrossRefPubMed
16.
Gaggini M, Morelli M, Buzzigoli E, et al. Nonalcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral
17.
Hamagushi M, Kojima T, Takeda N. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13(10):1579–84.CrossRef
18.
Choi DH, Lee SJ, Kang CD, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol. 2013;19(38):6453–7.CrossRefPubMedPubMedCentral
19.
Perera N, Indrakumar J, Abeysinghe WV, et al. Nonalcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37.CrossRefPubMedPubMedCentral
20.
Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49(5):1537–44.CrossRefPubMed
21.
Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gammaglutamyltransferase, and early carotid plaques. Hepatology. 2012;55(5):1406–15.CrossRefPubMed
22.
ZelberSagi S, Salomone F, Yeshua H, et al. Nonhighdensity lipoprotein cholesterol independently predicts new onset of nonalcoholic fatty liver disease. Liver Int. 2014;34(6):e128–35.CrossRef
23.
Wu S, Wu F, Ding Y, et al. Association of nonalcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and metaanalysis. Sci Rep. 2016;6:33386.CrossRefPubMedPubMedCentral
24.
Bonci E, Chiesa C, Versacci P, et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and metaanalysis. Biomed Res Int. 2015;213737:2015.
25.
Ridker PM, Hennekens CH, Buring JE, et al. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.CrossRefPubMed
26.
Assy N, Bekirov I, Mejritsky Y, et al. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic fatty liver diseases. World J Gastroenterol. 2005;11(37):5834–9.CrossRefPubMedPubMedCentral
27.
Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in nonalcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14(10):20704–28.CrossRefPubMedPubMedCentral
28.
Targher G, Bertolini L, Scala L, et al. Associations between serum 25hydroxyvitamin D3 concentrations and liver histology in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17(7):517–24.CrossRefPubMed
29.
Li XL, Sui JQ, Lu LL, et al. Gene polymorphisms associated with nonalcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis. 2016;15:53.CrossRefPubMedPubMedCentral
30.
Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(1):196–203.CrossRefPubMed
31.
Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325–30.CrossRefPubMed
32.
Madan SA, John F, Pyrsopoulos N, et al. Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a metaanalysis. Eur J Gastroenterol Hepatol. 2015;27(11):1237–48.CrossRefPubMed
33.
Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52(5):1643–165.CrossRefPubMed
34.
Weghuber D, Rodenm M, Franz C, et al. Vascular function in obese children with nonalcoholic fatty liver disease. Int J Pediatr Obes. 2011;6(2):120–7.CrossRefPubMed
35.
Torun E, Aydin S, Gökçe S, et al. Carotid intima media thickness and flowmediated dilation in obese children with nonalcoholic fatty liver disease. Turk J Gastroenterol. 2014;25(Suppl. 1):92–8.PubMed
36.
37.
Zieman S, Melenovsky V, Kass D. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932–43.CrossRefPubMed
38.
Johnson C, Baugh R, Wilson C, et al. Age related changes in the tunica media of the vertebral artery: implications for the assessment of vessels injured by trauma. J Clin Pathol. 2001;54(2):139–45.CrossRefPubMedPubMedCentral
39.
VilellaNogueira C, Leite N, Cardoso C, et al. NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms? Int J Mol Sci. 2016;17(4):460.CrossRef
40.
Harisson S. Nonalcoholic fatty liver disease and fibrosis progression:the good, the bad, and the unknown. Clin Gastroenterol Hepatol. 2015;13(4):655–7.CrossRef
41.
Shiotani A, Motoyama M, Matsuda T, et al. Brachialankle pulse wave velocity in Japanese university students. Intern Med. 2005;44(7):696–701.CrossRefPubMed
42.
Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens. 2010;23:1183–9.CrossRefPubMed
43.
Kim B, Kim N, Kim BS, et al. The association between nonalcoholic fatty liver disease,metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology. 2012;123:54–61.CrossRefPubMed
44.
Huang Y, Bi Y, Xu M, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middleaged and elderly Chinese. Arterioscler Thromb Vasc Biol. 2012;32:2321–6.CrossRefPubMed
45.
Huang C, Beilin J, Ayonrinde O, et al. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology. 2013;58(4):1306–14.CrossRefPubMed
46.
47.
Sunbulm A. Durmus E, et al. Arterial stiffness in patients with nonalcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237(2):490–3.CrossRef
48.
• Haradap BI, Drager F. Nonalcoholic fatty liver disease presence and severity is associated with aortic stiffness beyond abdominal obesity: the ELSABrasil. Atherosclerosis. 2019;284:59–65 This crosssectional study demonstrates the association of NAFLD with aortic stiffness in a racially/ethnically diverse population free of CVD. CrossRef
49.
50.
Lin Z. G, Zhang J, et al. Nonalcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis. 2015;25(2):218–23.CrossRef
51.
Silverman M, Blaha M, Krumholz H, et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the multiethnic study of atherosclerosis. Eur Heart J. 2014;35(33):2232–41.CrossRefPubMed
52.
Al Rifai M, Silverman M, Nasir K. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multiethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629–33.CrossRefPubMedPubMedCentral
53.
54.
Kim D, Choi S, Park E, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605–13.CrossRefPubMed
55.
Gummesson A, Strömberg U, Schmidt C. Nonalcoholicfatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a crosssectional, populationbased study in middleaged subjects. PLoS One. 2018;13(8):e0202666. https://​doi.​org/​10.​1371/​journal.​pone.​0202666eCollection 2018.
56.
• Cho Y, Kang Y, Yoo J. The impact of nonalcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep. 2018;8:12004 First study to demonstratethat NAFLD is an independent contributor to CAC progression, irrespective of the presence of metabolic syndrome. CrossRefPubMedPubMedCentral
57.
• Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019;282:110–20 Critical review of the association of NAFLD and CVD. CrossRefPubMed
Metadata
Title
Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis
Authors
Luan Rodrigues Abdallah
Ricardo Cardoso de Matos
Yves Pacheco Dias March e Souza
Débora Vieira-Soares
Gabriela Muller-Machado
Priscila Pollo-Flores
Publication date
01-01-2020
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 1/2020
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-020-0820-8

Other articles of this Issue 1/2020

Current Atherosclerosis Reports 1/2020 Go to the issue

Correction

Correction to: Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents

Nonstatin Drugs (R. Carmena, Section Editor)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

Reviews and New Research Implications (S. Virani, Section Editor)

Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions

Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever, Section Editor)

Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits